Diagnostics

Castle Biosciences’ DecisionDx®-SCC Data Earns Top Five Abstract at NCCN 2025, Shows Significantly Enhanced Risk Stratification Beyond Current Staging Within NCCN Risk Groups

New, combined validation cohort of 1,412 patients with high-risk squamous cell carcinoma (SCC) demonstrates that the addition of DecisionDx-SCC to...

Curium Completes the Acquisition of Monrol as Part of its Plan to Significantly Expand Lutetium-177 Capacity and PET Footprint

Positions Curium as leading manufacturer of Lu-177 isotopeBrings innovative R&D expertise and pipeline to Curium Enhances Curium’s SPECT & PET...

Single-cell Analysis Market Surges to USD 5.4 Billion by 2033, Propelled by 9.5% CAGR – Verified Market Reports®

The Single-Cell Analysis Market is experiencing robust expansion, driven by surging demand for precision medicine, advancements in genomics, and rising investments...

Belay Diagnostics Partners with GenomOncology to Support High-Performance Liquid Biopsy Test for Central Nervous System Cancer Detection

CLEVELAND, March 25, 2025 /PRNewswire/ -- Belay Diagnostics announces its partnership with GenomOncology (GO), a precision medicine software company that provides...

error: Content is protected !!